NCT06860529View on ClinicalTrials.gov

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

357

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2030

Conditions
HR+/HER2- Breast Cancer
Interventions
DRUG

Serplulimab

Serplulimab is administered intravenously

DRUG

Epirubicin

Epirubicin ivgtt

DRUG

Albumin Paclitaxel

Albumin Paclitaxel ivgtt

Trial Locations (1)

450000

RECRUITING

Henan cancer hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV